Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis after hepatic resection

Journal of Gastroenterology

Volumn 39, Issue 2, 2004, Pages 148-154

  Nanashima, Atsushi ^a   Yano, Hiroshi ^a   Yamaguchi, Hiroyuki ^a   Tanaka, Kenji ^a   Shibasaki, Shinichi ^a   Sumida, Yorihisa ^a   Sawai, Terumitsu ^a   Shindou, Hisakazu ^a   Nakagoe, Tohru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Hepatic resection; Hepatocellular carcinoma; Microvessel count; nm23; p53; PCNA

Indexed keywords

ALCOHOL; BIOLOGICAL FACTOR; CYCLINE; FLUOROURACIL; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN P53;

ADULT; AGED; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE DURATION; FACTORIAL ANALYSIS; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER LOBECTOMY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542285169     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1265-x     Document Type: Article

References (41)

1. Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, et al. Hepatic resection for hepatocellular carcinoma - Japanese experience. Hepatogastroenterology 1998;45: 1267-74.
2. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001:34: 707-14.
3. Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, et al. A prospective randomised trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996;87:206-11.
4. Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S, Rikimaru T, et al. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 2002;131(Suppl 1):148-52.
5. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995: 108:768-75.
6. Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001;8:404-9.
7. Sitruk V, Vaysse J, Chevret S, Gaime-Carrie N, Christidis C, Trinchet J, et al. Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients. Gastroenterol Clin Biol 2000;24:1159-63.
8. Terris B, Laurent-Puig P, Belghitti J, Degott C, Henin D, Flejou JF. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. Int J Cancer 1997;74:614-9.
9. Iizuka N, Oka M, Noma T, Nakazawa A, Hirose K, Suzuki T. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res 1995;55:652-7.
10. Boix L, Bruix J, Campo E, Sole M, Castells A, Fuster J, et al. nm23-H1 expression and disease recurrence after surgical resection of small hepatocellular carcinoma. Gastroenterology 1994; 107:486-91.
11. Zheng XY, Ling ZY, Tang ZY, Liu YK, Feng XL, Zhuang W. The abundance of NM23-H1 mRNA is related with in situ microenvironment and intrahepatic metastasis in hepato-cellular carcinoma. J Exp Clin Cancer Res 1998;17:337-41.
12. Chan GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-8.
13. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999;125:419-26.
14. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20:1775-85.
15. Chin JH, Wu LH, Kao HL. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma? Hepatology 1993;18:96-102.
16. Soini Y, Virkajarvi N, Lehto VP, Paakko P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 1996;73:1025-30.
17. Poon RT. Mg IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular-carcinoma. Am J Surg 2001;182:298-304.
18. Cottier M, Jouffre C, Maubon I, Sabido O, Barthelemy C, Cuilleron M, et al. Prospective flow cytometric DNA analysis of hepatocellular carcinoma specimens collected by ultrasound-guided fine needle aspiration. Cancer 1994;74:599-605.
19. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002;8:385-92.
20. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara; 2000. p. 11-34.
21. Liver Cancer Study Group of Japan. Classification of primary liver cancer. First English Ed. Tokyo: Kanehara; 1997. p. 5.
22. Nanashima A, Sekine I, Ito M, Naito S, Yamaguchi H, Nakagoe T, et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 1998;43: 2634-38.
23. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5.
24. Anonymous-Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994;74:2772-80.
25. Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037-44
26. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001;96:1243-50.
27. Hirohashi K, Shuto T, Kubo S, Tanaka H, Yamamoto T, Ikebe T, et al. Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus. J Hepatobiliary Pancreat Surg 2001;8:81-6.
28. Ko S, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Kin T, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. Ann Surg 1996;224:591-5.
29. Chiappa A, Zbar AP, Podda M, Audisio RA, Bertani E, Biella F, et al. Prognostic value of the modified TNM (Izumi) classification of hepatocellular carcinoma in 53 cirrhotic patients undergoing resection. Hepatogastroenterology 2001;48:229-34.
30. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994;106:720-7.
31. An FQ, Matsuda M, Fujii H, Tang RF, Amemiya H, Dai YM, et al. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 and beta-catenin. Int J Cancer 2001;93:468-74.
32. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36:151-69.
33. Tetu B, Brisson J, Plante V, Bernard P. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998;11:823-30.
34. Shimada M, Rikimaru T, Hamatsu T, Yamashita Y, Terashi T, Taguchi K, et al. The role of macroscopic classification in nodular-type hepatocellular carcinoma. Am J Surg 2001;182:177-82.
35. Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol 1995;26:326-33.
36. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, et al. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998;4:1475-82.
37. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-62.
38. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999;125:419-26.
39. Ueda K, Kitagawa K, Kadoya M, Matsui O, Takashima T, Yamahana T. Detection of hypervascular hepatocellular carcinoma by using spiral volumetric CT: comparison of US and MR imaging. Abdom Imaging 1995;20:547-53.
40. Yamamoto K, Shiraki K, Deguchi M, Sugimoto K, Sakai T, Ohmori S, et al. Diagnosis of hepatocellular carcinoma using digital subtraction imaging with the contrast agent, levovist: comparison with helical CT, digital subtraction angiography, and US angiography. Oncol Rep 2002;9:789-92.
41. Nonami T, Harada A, Kurokawa T, Nakao A, Takagi H. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997;173:288-91.